Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
about
The evolving roles and controversies of radiotherapy in the treatment of glioblastomaAdvances in the treatment of newly diagnosed glioblastomaCD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor ActivityGene therapy for brain tumors: basic developments and clinical implementationSui generis: gene therapy and delivery systems for the treatment of glioblastomaMicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cellsMultifunctional nanoparticles for brain tumor imaging and therapy.Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2Small-molecule agonists of mammalian Diaphanous-related (mDia) formins reveal an effective glioblastoma anti-invasion strategy.Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapyAdvanced magnetic resonance imaging of the physical processes in human glioblastoma.DCVax®-L--developed by Northwest BiotherapeuticsControversies in the adjuvant therapy of high-grade gliomas.Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group studyA single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastomaDeferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotypeInitial care and outcome of glioblastoma multiforme patients in 2 diverse health care scenarios in Brazil: does public versus private health care matter?.Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole.Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?Improved survival time trends for glioblastoma using the SEER 17 population-based registries.The Expression of Connexins and SOX2 Reflects the Plasticity of Glioma Stem-Like Cells.Trial Watch: Toll-like receptor agonists in oncological indications.Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.Photochemical internalization-mediated nonviral gene transfection: polyamine core-shell nanoparticles as gene carrier.Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy.Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells.Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.Towards personalized therapy for patients with glioblastoma.Bevacizumab for the treatment of recurrent glioblastoma.The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaCilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.Glioblastoma extracellular vesicles: reservoirs of potential biomarkers.Synthesis and biological evaluation of indolyl-pyridinyl-propenones having either methuosis or microtubule disruption activityMetallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model.
P2860
Q26746622-24F66FFA-3F1D-4388-9C7F-454A4C294735Q26773514-64465DB7-5A9B-4C54-85B3-E5D90F3FD118Q26782520-440C4E3B-BD32-4073-AFAD-6202E81AB410Q26829086-B37807E3-E6C5-4E72-84B7-9C4049ECEC07Q26850467-4FF269E6-B16E-4F03-A836-52F788070765Q26865287-18C04C1A-2DCE-4938-AFE5-45B5F6E59B1EQ26865418-80D2D2DE-4B3C-47E0-982A-E40107B2A12BQ27010096-2597792C-5157-485C-B98E-0AC1DFB7A770Q27306686-6C97D382-0001-4979-ABF1-10E9770DAB1AQ27334453-C1D772C2-8C6D-4DD2-9A67-57BD1C4E2921Q28564542-CFC1E78C-73E6-44E6-8BB9-AD086196A706Q30847284-5E4E2B2E-747C-46FD-B2B3-B39BE6F2E7A9Q30875456-ADFC13E3-94C6-4C1F-9418-EB82E4281564Q33394265-0C9623D1-6A43-4279-B2AA-A0F3BAB2891FQ33398291-9A6E4FE1-0224-4D73-AF37-55BD6FBB61C8Q33413997-F2D0F103-09C1-4452-BAAB-2E8B712377C5Q33616632-24DDDDF3-EF27-4F89-AFAE-A480A22AB264Q33631488-9E2B1398-F2D2-44D7-A97E-4E6A15C4C0AEQ33753453-065FBF51-EE77-4DB9-8FA5-D6752BBFC1A8Q33804001-F3AB7167-BADC-4488-A69F-8B85D5E9283EQ33828102-5D0D3A6C-DA18-4C88-BFA2-81938A1E38ACQ33828439-87BE22A0-F9A4-46DB-82DD-CA08BF867E7AQ33842621-093B5768-066F-4BA1-921B-8F158F55E3E9Q33878578-F3CC612B-7393-4714-B9C2-85D56FE3AB6AQ34000761-558D2048-6829-41BD-80F3-46119C4519EBQ34242939-D560FF9D-6811-4BB5-A962-861DC6C2BA04Q34347733-2D1A6D31-C163-42C4-9F6C-27AE7D459323Q34389909-85C2813C-E513-48E3-92A2-925F328A0109Q34434111-6E5C6BF4-BB4B-47E5-A52C-E297F7FC3FAFQ34460630-DF6D1BCF-1AD9-48DE-8DF6-6EBB97633EB6Q34480557-717ECE1B-0179-442D-9A5E-B545B54FB59DQ34679133-2C6FBC50-1D3E-42F0-81BB-8F953D533161Q34935862-A48481CE-5909-4430-8A72-A66ABB045CAEQ34978252-21B44ADB-5CDC-4689-9687-05294139C22EQ34982777-01234FCE-2A70-4647-894B-2D63473CC88CQ35053326-8E6A1AB0-AF60-42CD-85B4-349CFA8AA88EQ35078406-197D1FE8-DA8E-4546-ADFA-31AA3EADA75EQ35122209-946D8325-8766-450B-9093-0FECE071883FQ35179218-B20404E4-A302-4D46-8B46-5AB7C7F318B8Q35222408-5552D5F1-A879-4BCA-A967-DEEC0ED1ADD1
P2860
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Survival of patients with newl ...... studies in the United States.
@ast
Survival of patients with newl ...... studies in the United States.
@en
type
label
Survival of patients with newl ...... studies in the United States.
@ast
Survival of patients with newl ...... studies in the United States.
@en
prefLabel
Survival of patients with newl ...... studies in the United States.
@ast
Survival of patients with newl ...... studies in the United States.
@en
P2093
P2860
P50
P1476
Survival of patients with newl ...... h studies in the United States
@en
P2093
Joy Fisher
NABTT CNS Consortium
Serena Desideri
Stuart A Grossman
P2860
P304
P356
10.1158/1078-0432.CCR-09-3106
P407
P577
2010-04-06T00:00:00Z